Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized therapy to improve cure rate in high-risk BRCA1-like stage III breast cancer
2016-002493-13Phase 3Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olaparib in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Started Sep 2016; status: active.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002493-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002493-13.